Opus Genetics (IRD) Retained Earnings (2010 - 2026)
Opus Genetics (IRD) posted quarterly Retained Earnings of $208.3 million for Q1 2026, up 36.79% year-over-year from $152.3 million in Q1 2025, and up 2.13% quarter-over-quarter from $203.9 million in Q4 2025.
Opus Genetics (IRD) Retained Earnings (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Retained Earnings for 17 consecutive years, with $208.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 36.79% year-over-year to $208.3 million; the TTM figure through Mar 2026 stood at $208.3 million (up 36.79% YoY), while the FY2025 annual figure was $203.9 million, up 39.95% from the prior year.
- Retained Earnings advanced to $208.3 million in Q1 2026 per IRD's latest filing, from $203.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $208.3 million in Q1 2026 and bottomed at -$172.1 million in Q3 2025.
- Historically, Retained Earnings has averaged $84.4 million across 5 years, with a median of $119.9 million in 2023.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 283.79% — and 2025, when it slumped 224.54%.
- Opus Genetics' Retained Earnings stood at -$71.5 million in 2022, then jumped by 283.79% to $131.4 million in 2023, then rose by 10.92% to $145.7 million in 2024, then soared by 39.95% to $203.9 million in 2025, then grew by 2.13% to $208.3 million in 2026.
- Business Quant data shows IRD's Retained Earnings at $208.3 million in Q1 2026, $203.9 million in Q4 2025, and -$172.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -262.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -262.22 Mn |
| Mar 31, 2026 | 208.28 Mn |
| Dec 31, 2025 | 203.93 Mn |
| Sep 30, 2025 | -172.07 Mn |
| Jun 30, 2025 | 172.08 Mn |
| Mar 31, 2025 | 152.26 Mn |
| Dec 31, 2024 | 145.72 Mn |
| Sep 30, 2024 | 138.16 Mn |
| Jun 30, 2024 | -96.34 Mn |
| Mar 31, 2024 | -88.57 Mn |
| Dec 31, 2023 | 131.37 Mn |
| Sep 30, 2023 | 126.95 Mn |
| Jun 30, 2023 | 119.93 Mn |
| Mar 31, 2023 | 118.52 Mn |
| Dec 31, 2022 | -71.48 Mn |
| Sep 30, 2022 | 117.30 Mn |
| Jun 30, 2022 | 115.48 Mn |
| Mar 31, 2022 | 113.23 Mn |
| Dec 31, 2021 | 111.59 Mn |
| Sep 30, 2021 | -83.06 Mn |